Cero Therapeutics今日公布了其候选药物Cer-1236针对急性髓系白血病（AML）的I期临床试验（研究代号CERTAINT-1）的最新临床数据。此次更新重点展示了该疗法的关键安全性特征，并报告了一例同时患有骨髓增生异常综合征（MDS）和AML的患者，在接受治疗后观察到了无需输注血小板的间隔期。这一发现为评估Cer-1236的潜在临床益处提供了初步的积极信号。
Cero Therapeutics今日公布了其候选药物Cer-1236针对急性髓系白血病（AML）的I期临床试验（研究代号CERTAINT-1）的最新临床数据。此次更新重点展示了该疗法的关键安全性特征，并报告了一例同时患有骨髓增生异常综合征（MDS）和AML的患者，在接受治疗后观察到了无需输注血小板的间隔期。这一发现为评估Cer-1236的潜在临床益处提供了初步的积极信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.